ArticleJournal of pharmacy & bioallied sciences2025
Prognostic Value of High-Sensitivity Troponin I for Cardiovascular Risk Stratification in Chronic Kidney Disease Patients.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The onset of chronic kidney disease (CKD) results in a high level of cardiovascular morbidity and mortality. Conventional risk assessment systems tend to fail in considering the cardiovascular risk of this group of people. A biomarker of myocardial damage, high-sensitivity cardiac troponin I (hs-cTnI), has become a candidate biomarker of subclinical cardiac damage. Materials and Methods: A prospective observational study was carried out of 120 patients with CKD stages 3 to 5 that excluded dialysis patients. A high-sensitivity immunoassay was used to measure the baseline value of hs-cTnI. The follow-up was thorough, with patients being kept under observation after 12 months of occurrence in their patients major adverse cardiovascular events (MACE), i.e., myocardial infarction, heart failure hospitalization, and cardiovascular death. Results: Out of 120 CKD patients (mean age 58.2+/- 9.6 years; 62 males), 48 patients (40%) had elevated hs-cTnI (>19.0 ng/L). The number of patients who developed MACE at the time of the follow-up was 29 (24.2%). There was a significantly greater proportion of MACE in an elevated hs-cTnI group (52.1%) than in a normal hs-cTnI group (10.4%) ( Conclusion: High-sensitivity T-I is a good prognostic biomarker of cardiovascular events among CKD patients. Its regular evaluation can help in the initial classification of risks and selective cardiovascular preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.